Inclisiran, a Potent Lipid Lowering Treatment for Reaching LDL Goals on Top of Statins and Ezetimibe: A Single User Experiences
Main Article Content
Abstract
BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality, and reducing LDL cholesterol is a key strategy in lowering cardiovascular risk. Inclisiran, a small interfering RNA that targets PCSK9, is an effective lipid-lowering treatment.
AIM: This study evaluates the long-term efficacy of inclisiran in patients with high cardiovascular risk who fail to reach LDL goals despite statin and ezetimibe therapy.
METHODS: A total of 33 patients with high-risk atherosclerotic disease and elevated LDL cholesterol levels, despite maximal statin/ezetimibe therapy or patients who couldn't tolerate statins, were administered inclisiran at baseline with 21 patients receiving a second dose at 3 months. Lipid profiles were measured at baseline, 3 months after first dose, and 3 months after second dose. The primary outcome was the change in LDL-C levels from baseline to post-treatment.
RESULTS: Inclisiran significantly reduced LDL-C levels from a baseline mean of 2.66 mmol/L to 1.49 mmol/L after the first dose (p < 0.001). A total of 73.0% of patients achieved LDL-C levels below 1.8 mmol/L, 57.7% below 1.4 mmol/L, and 34.6% below 1.0 mmol/L, with 42.3% experiencing a reduction of more than 50% after the first dose. These reductions were maintained after the second dose, with LDL-C levels remaining significantly lower than baseline.
CONCLUSION: Inclisiran provides significant and sustained LDL-C reductions in patients with high cardiovascular risk and represents an effective long-term treatment option for reducing cardiovascular risk.
Downloads
Article Details

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
References
1. Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet. 2018 Nov 10;392(10159):2052-2090. https://doi.org/10.1016/S0140-6736(18)31694-5. Epub 2018 Oct 16. PMID: 30340847; PMCID: PMC6227505.
2. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017 Aug 21;38(32):2459-2472. https://doi.org/10.1093/eurheartj/ehx144 PMID: 28444290; PMCID: PMC5837225. 3. Wright RS, Ray KK, Raal FJ, Kallend DG, Jaros M, Koenig W, et al. Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis. J Am Coll Cardiol. 2021 Mar 9;77(9):1182-1193. https://doi.org/10.1016/j.jacc.2020.12.058. PMID: 33663735.
4. Banach M, Reiner Z, Surma S, Bajraktari G, Bielecka-Dabrowa A, Bunc M, et al 2024 Recommendations on the Optimal Use of Lipid-Lowering Therapy in Established Atherosclerotic Cardiovascular Disease and Following Acute Coronary Syndromes: A position paper of the International Lipid Expert Panel (ILEP). Drugs, 2024, in press. https://doi.org/10.1007/s40265-024-02105-5
5. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Jun 18;139(25). Erratum in: Circulation. 2023 Aug 15;148(7). https://doi.org/10.1161/CIR.0000000000001172. PMID: 30586774; PMCID: PMC7403606.
6. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227-3337. https://doi.org/10.1093/eurheartj/ehab484. Erratum in: Eur Heart J. 2022 Nov 7;43(42):4468. https://doi.org/10.1093/eurheartj/ehac458. PMID: 34458905.
7. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023 Oct 12;44(38):3720-3826. Erratum in: Eur Heart J. 2024 Apr 1;45(13):1145. https://doi.org/10.1093/eurheartj/ehad870. PMID: 37622654.
8. Lee B, Hong SJ, Rha SW, Heo JH, Hur SH, Choi HH, et al. Moderate-intensity statin plus ezetimibe vs high-intensity statin according to baseline LDL-C in the treatment of atherosclerotic cardiovascular disease: A post-hoc analysis of the RACING randomized trial. Atherosclerosis. 2023 Dec;386:117373. https://doi.org/10.1016/j.atherosclerosis.2023.117373. Epub 2023 Nov 10. PMID: 37995599.
9. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017 May 4;376(18):1713-1722. Epub 2017 Mar 17. https://doi.org/10.1056/NEJMoa1615664 PMID: 28304224.
10. Inclisiran (Leqvio). In: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. 2022 Jun 20. Available from: https://www.ncbi.nlm.nih.gov/books/NBK595412/
11. Koren MJ, Rodriguez F, East C, Toth PP, Watwe V, Abbas CA, et al. An "Inclisiran First" strategy vs usual care in patients with atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2024 May 21;83(20):1939-1952. https://doi.org/10.1016/j.jacc.2024.03.382. Epub 2024 Apr 7. PMID: 38593947.
12. Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020 Apr 16;382(16):1507-1519. https://doi.org/10.1056/NEJMoa1912387. Epub 2020 Mar 18. PMID: 32187462.
13. Banach M, Reiner Z, Cicero AFG, Sabouret P, Viigimaa M, Sahebkar A, et al. 2022: the year in cardiovascular disease - the year of upfront lipid-lowering combination therapy. Arch Med Sci. 2022 Nov 7;18(6):1429-1434. https://doi.org/10.5114/aoms/156147. PMID: 36457968; PMCID: PMC9710261.
14. Robinson JG, Jayanna MB, Brown AS, Aspry K, Orringer C, Gill EA, et al. Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit: a consensus statement from the National Lipid Association. J Clin Lipidol. 2019 Jul-Aug;13(4):525-537. https://doi.org/10.1016/j.jacl.2019.05.005. Epub 2019 May 16. PMID: 31281070.